patent.fyi
Applications  /  US 2026/0355267
United States Patent Application Publication

US 2026/0355267 A1

Published
Nov 12, 2026
Filed
Oct 24, 2023
Earliest date on the face
Oct 25, 2022
Classification
A61K 35/76
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Reference by archived image

What ifWhat if the reference record used an archived electron micrograph to document particle morphology?
Claim language“genome of the bacteriophage deposited under”

The image record stores a calibrated scale bar and views of representative particles. Head dimensions and visible tail features support comparisons between images.

1.2Reference by sample identifier

What ifWhat if the inventory identified each archived sample through a unique vial barcode?
Claim language“the nucleotide sequence of SEQ ID NO: 1”

A scanner reads the code and retrieves the corresponding lot and storage records from a database. Each movement updates the vial's recorded location while retaining its identifier.

1.3Comparison by particle dimensions

What ifWhat if the comparison used distributions of measured particle dimensions?
Claim language“overall sequence identity”

Calibrated micrographs provide head width and tail length measurements for particles with clearly visible outlines. The comparison reports the median and interquartile range for each dimension.

1.5Heat treatment of equipment

What ifWhat if equipment decontamination used a closed hot-water cycle?
Claim language“comprising a preservative”

A recirculation pump moves heated water through the equipment and back to the heating vessel. A temperature probe at the return line records the hold period used to verify the cycle.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Trehalose replaces the liquid preservative

Trehalose serves as the stabilizer for a freeze-dried preparation of a lytic phage that infects a nonpathogenic laboratory host. The phage and trehalose occupy a sealed vial, and sterile buffer occupies a separate vial. Reconstitution dissolves the dry cake, and a plaque assay on the laboratory host measures the infectious phage recovered from the vial.

Parameter or scale variation

Single use aliquots for bench assays

A stabilized suspension of a phage for a nonpathogenic laboratory host is dispensed in 0.5 mL portions into 2 mL screw-cap tubes. Ten tubes from each fill are reserved for storage checks, with two tubes assigned to each of five sampling dates. Each tube is opened once, and its plaque count is compared with the count measured at filling.

Combination with existing systems

Phage suspension in a microplate reader

A 96-well absorbance plate reader tracks growth of a nonpathogenic laboratory host exposed to a stabilized phage suspension. Separate well groups contain host with phage, host with carrier alone, and carrier without host. The reader records optical density over time, and the carrier-only wells provide the background for comparing the two host groups.

Refrigerated storage with vial temperature logging

A laboratory refrigerator holds sealed vials of a stabilized phage preparation for a nonpathogenic host. A temperature probe sits in a liquid-filled reference vial on the same rack, and a data logger records readings against time. A barcode on each storage tray links the temperature record to the lot, and a plaque assay measures activity after a recorded temperature excursion.

Automated or data-driven variant

Image based counting of lysis plaques

A fixed camera captures backlit images of agar plates prepared with a nonpathogenic laboratory host and dilutions of a stabilized phage suspension. Software locates the plate rim, masks the edge, and identifies discrete clear regions within the bacterial lawn. The software flags merged regions for review and combines the accepted count with the recorded dilution and plated volume to calculate plaque-forming units per milliliter.

Specific version of a part

Archived reference genome record

A read-only reference record stores the deposited genome sequence as a nucleotide text file and links it to the corresponding accession. A file checksum verifies that the archived copy retains the same bytes.

Exact nucleotide sequence record

A sequence database stores the specified nucleotide sequence as a text field. A direct equality check compares the complete nucleotide strings after removing line breaks and normalizing letter case.

Whole genome identity report

A report records the overall sequence identity between two existing genome records and identifies the deposited reference. It retains the reference version and the denominator used for the reported percentage.

Versioned nucleotide reference file

A single-record sequence file stores the specified nucleotide string with a header that identifies the reference and its version. A separate catalog entry records the sequence length in bases and links to the archived file.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2017/0283779 A1
Published
Oct 5, 2017
Filed
Mar 27, 2017
Class
C12N 7/00
Document BUS 11,311,582 B2
Published
Apr 26, 2022
Filed
Nov 18, 2016
Class
A61K 35/76
Claim 1
Document A
Document B
1.1(i). a genome comprising an overall sequence identity with at least 70% of the genome of the bacteriophage deposited under Accession No. NCIMB44022;
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences.
A · US 2017/0283779 A1 · ¶ 52
In some embodiments, there is provided a composition comprising a bacteriophage and a delivery vehicle, wherein the bacteriophage targets Escherichia coli, and wherein the bacteriophage comprises a genome having at least about 95% (such as 100%) sequence identity to the genome sequence of p0031 (IDAC Accession Number: 161116-01).
B · US 11,311,582 B2 · ¶ 12
1.2(ii). a genome comprising the nucleotide sequence of SEQ ID NO: 1, or a genome comprising at least 70% overall sequence identity with the nucleotide sequence of SEQ ID NO:1;
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences.
A · US 2017/0283779 A1 · ¶ 52
In some embodiments, the bacteriophage comprises a genome sequence having at least about 95% (such as 100%) sequence identity to SEQ ID NOs: 1-5.
B · US 11,311,582 B2 · ¶ 11
1.3(iii). a genome comprising an overall sequence identity with at least 70% of the genome of the bacteriophage deposited under Accession No. NCIMB44023; and
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences.
A · US 2017/0283779 A1 · ¶ 52
In some embodiments, there is provided a composition comprising a bacteriophage and a delivery vehicle, wherein the bacteriophage targets Escherichia coli, and wherein the bacteriophage comprises a genome having at least about 95% (such as 100%) sequence identity to the genome sequence of p0032 (IDAC Accession Number: 161116-02).
B · US 11,311,582 B2 · ¶ 13
1.4(iv). a genome comprising the nucleotide sequence of SEQ ID NO: 2, or a genome comprising
In some embodiments, the bacteriophage comprises a genome sequence having at least about 95% (such as 100%) sequence identity to SEQ ID NOs: 1-5.
B · US 11,311,582 B2 · ¶ 11
1.5at least 70% overall sequence identity with the nucleotide sequence of SEQ ID NO:2, and a pharmaceutically, veterinary or environmentally acceptable excipient or carrier comprising a preservative in an amount effective to preserve the substantial lytic activity of the at least one bacteriophage.
A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences.
A · US 2017/0283779 A1 · ¶ 52
When prepared as injectables, the bacteriophages disclosed herein can be generally administered using a pharmaceutically acceptable vehicle or excipient. Suitable vehicles are, for example, water, saline, mannitol, dextran, amino acids, glycerol, or the like, in various combinations, in addition, if desired, the vehicle may contain auxiliary substances such as wetting or emulsifying agents, preservatives and pH buffering agents.
B · US 11,311,582 B2 · ¶ 172

An empty cell means only that no passage was reproduced there.

Statements in these documents
The natural host range of model phage engineered to date is limited.
A · US 2017/0283779 A1 · ¶ 4
Methods for creating variations in phage genomes and engineering new phage genomes may lead to the identification of phages with varied properties (e.g., varied host ranges) that are useful for diagnostic and therapeutic purposes.
A · US 2017/0283779 A1 · ¶ 4
The present application relates to bacteriophage compositions, and methods of treating or preventing bacterial infections using the bacteriophage compositions.
B · US 11,311,582 B2 · ¶ 2
Therefore, there remains a need for finding a solution to the costly problem of bacterial infection and colonization in dairy herds leading to clinical and sub-clinical mastitis.
B · US 11,311,582 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355267 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355267/, SHA-256 dbd3525a4e1c4c116be8a6e97c5c375db606fa7518dd37fff28f8a05fcbdd1af
First published
Permanent addresshttps://patent.fyi/US20260355267/
Content fingerprint (SHA-256)dbd3525a4e1c4c116be8a6e97c5c375db606fa7518dd37fff28f8a05fcbdd1af
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi